NASDAQ · RNA
Healthcare · Biotechnology
$8.55
Up+$0.17 (+1.99%)
Updated Nov 3, 2026, 9:17 PM
SID Score
4.6/10
Composite research score
Smart Money
58/100
Neutral
Price performance · RNA
1M range · 0 trading sessions · Daily adjusted prices
RNA does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning RNA.
Company
Market Activity
Research & News
RNA research
Company profile and research snapshot.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 28, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 22, 2026 | Roth Capital | Buy | — |
| Aug 14, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 6, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 18, 2026 | Cantor Fitzgerald | Overweight | — |
No generated briefing is available yet.
Benzinga · Oct 28, 2026
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Atrium Therapeutics (NASDAQ:RNA) with a Buy and lowers the price target from $25 to $20.
Yahoo · Oct 27, 2026
Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that the first patient has been dosed in the Phase 1/2 Corventis clinical trial evaluating ATR 1072, its lead investigational therapy for the potential treatment of PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome. The Company expects to report initial proof-of-concept data from Corven
Benzinga · Oct 27, 2026
Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that the first patient has
Benzinga · Oct 22, 2026
Analysts initiated coverage: Buy ratings for CleanSpark, Constellation Energy and Atrium; Outperform for Kardigan; Neutral for Northwest Natural.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RNA.
